Cancer may Not be So Formidable in the Next 20 Years

As cancer survival statistics have shown marked improvement, it might not be so deadly afterall in the next twenty years , says a British expert.

Karol Sikora, professor of Cancer Medicine at Imperial College London, has said that the treatments for the disease are undergoing a "revolution", which means that within just two decades, "we will simply run out of things from which to die."

Survival Predictors May Help Customize Treatment Options For Prostate Cancer Patients
Four risk factors that help predict how long men may survive with metastatic prostate cancer could help doctors choose more effective treatments, according to a study led by researchers

And rather than facing a possible death sentence, cancer patients will be treated as if they have a long-term illness like diabetes, heart disease or asthma.

Sikora said that better technologies, better delivery systems to treat the disease, and financial constraints are expected in the near future.

And as improved cancer care leads to better survival rates, higher prevalence of the disease in our populations will lead to greater societal pressures as people will be expecting much more from medicine.

Relationship Between Cancer Stem Cells and Prognosis in Primary Breast Cancer Found
ORLANDO - Breast cancer patients who received chemotherapy prior to surgery had heightened levels of cancer-initiating stem cells in their bone marrow, and the level of such cells

"Within 20 years cancer will be a chronic disease, joining conditions such as diabetes, heart disease and asthma," the Daily Express quoted Sikora as saying.

"These conditions impact on the way people live and do not inexorably lead to death.

DNA Origami - DNA 'Medicine Cabinets' To Revolutionise Cancer Treatment
Scientists have made a significant advance in DNA origami which may one day enable drugs to be delivered from minuscule medicine cabinets made of DNA, and thereby revolutionise treatment of cancer.

"The model of prostate cancer, where many men die with it rather than from it, will be common for most cancers.

"Even greater progress will be made in understanding myriad causes of cancer," Silora added.

A report authored by Sikora appears on scripnews.com, published by Informa Pharma.

Source-ANI
SAV